Welcome to our dedicated page for Thc Therapeutics SEC filings (Ticker: THCT), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Thc Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Thc Therapeutics's regulatory disclosures and financial reporting.
THC Therapeutics, Inc. reports another development-stage year with no revenues and a net loss of $811,562 for the year ended July 31, 2024. The company continues to focus on its patented dHydronator herb dryer for cannabis and other plants.
Liquidity is extremely tight, with only $35 in cash, total assets of $10,648, and a working capital deficit of about $3.7M. Accumulated deficit reached roughly $39.2M, and auditors and management highlight substantial doubt about the company’s ability to continue as a going concern without new financing.